Search

Displaying results 1521 - 1530 of 8517 in total
  1. Drug

    Bleomycin

    go.drugbank.com/drugs/DB00290
    ApprovedInvestigational

    It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. … A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0).

  2. Drug

    Sotatercept

    go.drugbank.com/drugs/DB12118
    ApprovedInvestigational

    [A263481] Sotatercept was approved by the European Commission on August 26, 2024.[L51549] … [L50351] On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension (PAH).

  3. Drug

    Tedizolid

    go.drugbank.com/drugs/DB14569
    ApprovedInvestigational

    This product is currently available as both an oral tablet and as a powder for intravenous injection.[L11232] … [L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).

  4. Drug

    Lisdexamfetamine

    go.drugbank.com/drugs/DB01255
    ApprovedInvestigational

    [A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009. … Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine,[A40246] covalently attached to the naturally occurring amino acid L-lysine.

  5. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    [L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment

  6. Drug

    Isoprenaline

    go.drugbank.com/drugs/DB01064
    ApprovedInvestigational

    [L33204] Isoprenaline was granted FDA approval on 19 February 1948.[L33155] … [A15638,L33160] Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising the heart rate and cardiac output, without vasoconstriction

  7. Drug

    Acyclovir

    go.drugbank.com/drugs/DB00787
    ApprovedInvestigational

    [L7321] Acyclovir was granted FDA approval on 29 March 1982.[L7318] … [L7303,L7315,L7318,L7321,L7324,L7327] Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young as 6 years old.

  8. Drug

    Efalizumab

    go.drugbank.com/drugs/DB00095
    ApprovedWithdrawn

    It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797] … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.

  9. Drug

    Potassium

    go.drugbank.com/drugs/DB14500
    ApprovedInvestigational

    It was identified as a shortfall nutrient by the 2015-2020 Advisory Committee of Dietary Guidelines for Americans. … Hypokalemia (low potassium) or hyperkalemia (high potassium) may result, manifesting as various signs and symptoms.

  10. Drug

    Palovarotene

    go.drugbank.com/drugs/DB05467
    Approved

    It first garnered interest as a potential treatment for emphysema but was eventually recognized as a potential novel therapy for patients with FOP. … [L39990,L40020] It has been granted rare pediatric disease and breakthrough therapy designations from the US FDA, although a previously submitted NDA was withdrawn in August 2021 pending the resubmission